Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: A prospective follow-up study in patients with schizophrenia

Acta Psychiatrica Scandinavica

Volumn 116, Issue 5, 2007, Pages 354-361

  Hofer, A ^a   Rettenbacher, M A ^a   Edlinger, M ^a   Kemmler, G ^a   Widschwendter, C G ^a   Fleischhacker, W W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antipsychotics; Drug attitude; Psychopathology; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE; BIPERIDEN; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; AMENORRHEA; ANALYTIC METHOD; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE DURATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; HYPERSALIVATION; MALE; MENTAL DISEASE; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SCHIZOPHRENIA; SEDATION; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP; SLEEP DISORDER; WEIGHT GAIN;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 35148896834     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2007.01087.x     Document Type: Article

References (31)

1. Fleischhacker WW. Pharmacological treatment of schizophrenia: a review. In : Maj M, Sartorius N, eds. Schizophrenia. 2nd edn, Chichester : Wiley, 2002 : 75 113.
2. Biehl H, Maurer K, Schubart C, Krumm B, Jung E. Prediction of outcome and utilization of medical services in a prospective study of first onset schizophrenics. Results of a prospective 5-year follow-up study. Eur Arch Psychiatry Neurol Sci 1986 236 : 139 147.
3. Barnes TRE, Christopher J, Mcevedy B. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry 1996 169 : 31 40.
4. Kemp R, Hayward D, David A. Compliance therapy manual. London : Institute of Psychiatry, 1997.
5. Coldham L, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002 106 : 286 290.
6. Fleischhacker WW, Hofer A, Hummer M. Managing schizophrenia: the compliance challenge. London : Science Press LTD, 2003
7. Lacro JP., Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002 63 : 892 909.
8. Awad AG, Voruganti LNP, Heslegrave RJ, Hogan TP. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996 11 (suppl. 2 55 59.
9. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002 63 : 49 53.
10. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004 65 : 1372 1376.
11. Adewuya AO, Ola BA, Mosaku SK, Fatoye FO, Eegunranti AB. Attitude towards antipsychotics among outpatients with schizophrenia in Nigeria. Acta Psychiatr Scand 2006 113 : 207 211.
12. Day JC, Bentall RP, Roberts C et al. Attitudes toward antipsychotic medication. The impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005 62 : 717 724.
13. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987 13 : 261 276.
14. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. J Nerv Ment Dis 1994 182 : 631 638.
15. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res 1995 14 : 229 234.
16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale - a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987 334 : 1 100.
17. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983 13 : 177 183.
18. Lambert M, Schimmelmann BG, Naber D et al. Prediction of remission as a combination of symptomatic and functional remission and adequate well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006 67 : 1690 1697.
19. Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007 115 : 106 113.
20. Karow A, Czekalla J, Dittmann RW et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007 68 : 75 80.
21. Hofer A, Fleischhacker WW. Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand 2006 113 : 161 162.
22. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003 160 : 1209 1222.
23. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003 36 : 105 112.
24. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000 43 : 135 145.
25. Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005 111 (suppl. 427 29 34.
26. Naber D, Moritz S, Lambert M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001 50 : 79 88.
27. Fleischhacker WW, Meise U, Günther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994 89 (suppl. 382 11 15.
28. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996 93 : 381 388.
29. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 2005 111 (suppl. 427 43.
30. Haro JM, Edgell ET, Novick D et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results for the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005 111 : 220 231.
31. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995 10 (suppl. 3 133 138.